非主流

从10年到4.5年 “钱塘造”创新药 怎么把研发时间砍掉一半多？_我的网站

一 |     Europe’s leading hotelier Accor - a French international hospitality business with billions in revenue and more than 5,100 hotels - is now beginning “trials” to hire people with no experience in the hotel industry, the company’s chief executive Sebastien Bazin said, as it struggles to fill at least 35,000 vacancies.,“We tried in Lyon and Bordeaux 10 days ago and this weekend we're having people interviewed with no CV, no previous job experience and they are hired within 24 hours," Bazin said.,Since underpaid workers left the company, Accor is now filling those positions with those who are desperate for work such as students and/or expats.,Those who are practically hired on the spot by the multi-billion dollar company are trained in only six hours and are forced to learn on the job. The company will also limit their contact with customers as they struggle with staffing.,"It's students, people coming from North Africa," Bazin said, "and basically closing restaurants for lunch or [opening them] only five days a week. There's no other solution.",Some hoteliers will have to increase pay to find the help they need this tourist season. Spain’s tourism sector supported 13.5 percent of their workforce in 2018 - before the pandemic - and accounted for 11.8 percent of their gross domestic product in 2017. But Spain’s catering industry is at present short some 200,000 workers, and Portugal is fighting to increase staff at their hotels to keep pace with increasing demand.,"Many employees have decided to move to other sectors, so we are starting an industry from scratch and we have to fight for talent," said Gabriel Escarrer, chief executive of Spanish hotel group Melia which, along with other hospitality businesses, is reportedly offering higher wages than previously, health insurance, and free accommodation - though that last perk could be more a reflection of the shortage of housing near resorts.,However, hoteliers such as Hotel Mundial - located in Lisbon, Portugal - are facing the far from ideal decision of cutting services if they can’t find staff, and those who employ students will have to juggle rotas to accommodate their schedules.,“During the week we can't open because we have no hands - they are studying,” said Jose Carlos, who owns a bar in Madrid called Tabanco de Jerez.,Spain's hospitality industry is now paying 60 percent more than it did last year, on average, in an attempt to lure workers back to the force - however, those working in the tourism industry are still among the lowest-paid workers.,"Half of it is we've been blind, we've been not paying attention to a lot of people and probably underpaying some people for too long as well," said Bazin, who is worried his company won’t have enough staff when the summer rush, which is the height of the tourist season - arrives. "So it's a wake-up call.",One of the best documented reasons for people leaving their job during 'The Great Resignation' was because they were being paid too little. Another reason was the lack of professional advancement within the industry.,Other reasons people quit in 2021 included: feeling disrespected, lack of flexibility in scheduling, and a lack of benefits such as healthcare and paid holiday, according to a Pew Research Center survey. That same survey found that those who quit their job were able to find new places of employment that offered them better pay and more opportunities.。

二 |     AI设计的口服减重药有望2028年底上市 钱塘区生物医药产值已突破500亿元 近日，杭州德睿智药科技有限公司宣布完成累计5200万美元B轮融资。2026年1月，杭州医药港，德睿智药一款名叫MDR-001的口服减重药，以令全球医药界瞩目的速度，启动Ⅲ期临床试验，成为国内首个进入临床Ⅲ期的AI小分子新药。这家仅40多人的公司，把一款一类创新药从立项到推进至Ⅲ期临床的时间，压缩到了4.5年。而传统同行完成同样的路程，通常需要8到12年。不用“大海捞针”了2021年初，85后海归博士牛张明，带着计算机和生物制药2个硕士学位、5种AI算法语言，在钱塘区成立了德睿智药。当时，他就想好了：“要走一条和传统制药完全不同的路。”传统新药研发有多难？业内有个“双十定律”，即成功研发一款创新药，平均需要10年的时间和10亿美元的投入。面对超过10的60次方级别、近乎无限的成药化学空间，科学家们只能靠经验和反复试错，如同在茫茫大海里捞针。牛张明说：“过去的药物发现，靠大量实验、反复试错，不仅耗时间，成功率也低。现在用上AI，好比给每位科学家配了一个‘超级大脑’做助手。”2026年，德睿智药基于MDR-001的研发流程，搭建起了由多智能体驱动的全链条AI制药引擎MAP。这个平台覆盖靶点发现、分子设计、多目标优化、实验验证及临床试验全链条。“药物分子就像精密的拼图，每个片段都决定着药效和安全性。以往，这全靠科研人员的经验和反复试错。”牛张明解释，“MAP能通过学习海量已知药物的成功与失败案例，自动预测分子片段的性质，大幅减少试错成本、缩短研发周期。

三 | ”他打了一个比方：“你可以把它想象成一位高效且永不疲倦的‘分子组装专家’，在虚拟世界里高速筛选，帮研发人员提前排除大量‘错误选项’。”药物研发，就这样从“大海捞针”变成了“高清导航”。口服减重新药将于2028年底上市MDR-001是一款GLP-1（胰高血糖素样肽-1）受体激动剂，与市面上常见的减肥注射剂最大的不同在于，它可以口服。

四 | “我们立项时，口服GLP-1还没有出现。口服小分子药物的依从性更高，患者不需要消毒针头注射、不需要低温冷藏保存，使用更方便；在某些适应证上疗效甚至优于注射剂型。”牛张明说。

五 | 在MDR-001项目中，团队仅耗时8个月、实际仅合成80个小分子，就获得了高质量的临床前候选药物。从立项到推进至Ⅲ期临床研究，整体仅耗时4.5年，单产品累计研发投入控制在约2300万美元。对比传统同类药物的研发周期和投入，这组数字可以称得上是“奇迹”了。“从临床前阶段来看，AI制药平台可节省50%至70%的研发成本，并将研发周期缩短50%以上。”牛张明说。

六 | 目前，MDR-001的Ⅲ期临床进展顺利，已在国内完成760名受试者招募，合作临床中心近50家。在已完成的IIb期临床试验中，317名平均体重约90公斤的受试者在用药24周后，体重平均降幅达10.3%，因不良反应导致的停药率仅为0.8%。如果一切顺利，这款“钱塘智造”的口服减重新药，有望于2028年底或2029年初上市。

七 |

Current article:http://99r3o7f.zhuaicaisaanzhenshunnaiwei.bond/l4bneq4/becc.html

Published on:05:05:28